The combination of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype anti-PD-L1 and bevacizumab, a monoclonal antibody anti-VEGF, resulted in 61% partial response among 21 HCC patients with a relatively positive tolerability characterized by 35% of the subjects experiencing grade III/IV adverse events [45]. Here, VEGFA is linked to hepatocellular carcinoma.